| Schedule of Basic and Diluted Net Loss Per Share |
The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss |
|
$ |
(9,298 |
) |
|
$ |
(9,225 |
) |
|
$ |
(17,921 |
) |
|
$ |
(18,643 |
) |
Numerator for Basic and Dilutive EPS – Loss available to common stockholders |
|
$ |
(9,298 |
) |
|
$ |
(9,225 |
) |
|
$ |
(17,921 |
) |
|
$ |
(18,643 |
) |
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock |
|
|
99,797,156 |
|
|
|
78,077,118 |
|
|
|
98,751,951 |
|
|
|
76,893,733 |
|
Denominator for Basic and Dilutive EPS - Weighted-average common stock |
|
|
99,797,156 |
|
|
|
78,077,118 |
|
|
|
98,751,951 |
|
|
|
76,893,733 |
|
Basic and dilutive net loss per share |
|
$ |
(0.09 |
) |
|
$ |
(0.12 |
) |
|
$ |
(0.18 |
) |
|
$ |
(0.24 |
) |
|
| Schedule of Anti-dilutive Common Equivalent Shares |
Anti-dilutive common equivalent shares were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Outstanding options to purchase common stock |
|
|
15,688,709 |
|
|
|
17,016,565 |
|
|
|
15,688,709 |
|
|
|
17,016,565 |
|
Outstanding RSUs |
|
|
5,921,884 |
|
|
|
2,567,691 |
|
|
|
5,921,884 |
|
|
|
2,567,691 |
|
Warrants issued in connection with February 2025 Offering |
|
|
4,257,419 |
|
|
|
4,511,178 |
|
|
|
4,257,419 |
|
|
|
4,511,178 |
|
Warrants issued in connection with Loan Agreement |
|
|
562,500 |
|
|
|
— |
|
|
|
562,500 |
|
|
|
— |
|
Total anti-dilutive common equivalent shares |
|
|
26,430,512 |
|
|
|
24,095,434 |
|
|
|
26,430,512 |
|
|
|
24,095,434 |
|
|